Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02869126
Other study ID # 2012-A00569-34
Secondary ID
Status Completed
Phase N/A
First received August 9, 2016
Last updated August 11, 2016
Start date September 2012
Est. completion date November 2015

Study information

Verified date August 2016
Source Central Hospital, Nancy, France
Contact n/a
Is FDA regulated No
Health authority France: Agence Nationale de Sécurité du Médicament et des produits de santé
Study type Interventional

Clinical Trial Summary

The purpose is to demonstrate the concordance of diagnostic information obtained with:

1. a conventional examination with 2 distinct recordings on D.SPECT camera after 99mTc-sestamibi injections, the first post-stress and the second at rest, 2 to 3 hours later,

and

2. a double isotope examination with a supplementary recording after injection of a little activity of thallium-201 at rest after the first recording and before the second injection of 99mTc-sestamibi for conventional recording at rest,

in patients showing abnormalities of myocardial perfusion in stress myocardial tomoscintigraphy.


Description:

Myocardial perfusion tomoscintigraphy is very used for diagnosis and characterization of abnormalities of stress and rest myocardial perfusion. This examination can be performed with semiconductor gamma cameras that are more performant than conventional cameras regarding spatial resolution, detection sensitivity and energy resolution.

The amelioration of energy resolution could allow the realization of simultaneous recordings of a dye injected at rest and another injected during stress (double isotope recording), while conventional examination needs 2 different recordings, stress and rest, separated from several hours.

In this study patients undergo a conventional examination with D.SPECT camera with 2 recordings, the first after injection of a little activity of 99mTc-sestamibi at stress (≤ 100 MBq) and the second, 2 hours later, after injection at rest of a 3 time bigger activity of 99mTc-sestamibi (≤ 300 MBq). An activity of thallium-201(≤ 50 MBq) is injected at rest after the first recording of stress. 5 minutes later, a supplementary double isotope recording is realized with D.SPECT camera (99mTc-Sestamibi-stress / thallium201-rest).

The demonstration of the hypothesis of this study could considerably diminish the duration of the examination (from 3 to 4 hours to less than 1 hour).


Recruitment information / eligibility

Status Completed
Enrollment 118
Est. completion date November 2015
Est. primary completion date November 2015
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- > 18, without guardianship, signed informed consent

- Without contraindication for myocardial perfusion tomoscintigraphy and stress technique (dipyridamole and/or effort), according to common criteria to French Societies of Cardiology and Nuclear Medicine, as it is requested for all patients needing this routine examination

- Not in life-and-death emergency, with a stable clinical state (without cardiac insufficiency or instable coronary, without hypertension not well-stabilized under treatment)

- Effective contraceptive method for women of childbearing potential

- Weight = 100 kg (> 100 kg patients need higher injected activities in order to obtain adequate image quality)

- Perfusion abnormalities on stress images

Exclusion Criteria:

- < 18

- Contraindications to stress test (effort and/or dipyridamole)

- Hypersensibility to thallium201 chloride or one of excipients

- Claustrophobic patient or incapable to stay lying down for 30 minutes

- Pregnancy or doubt of pregnancy

- Breastfeeding woman

- Weight > 100 kg

- Non affiliation to social security plan

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic


Related Conditions & MeSH terms


Intervention

Procedure:
Tomoscintigraphy with D.SPECT camera (SPECTRUM Dynamics®, Israel)
During stress test, intravenous injection of 99mTc-Sestamibi (between 80 and 150 MBq according to weight) in patient Stress conventional acquisition with D.SPECT camera 20 min after injection 60 min after 99mTc-Sestamibi injection, rest injection of thallium-201 (50% activity of stress 99mTc-Sestamibi) double isotope acquisition 5 min after thallium-201 injection injection of 99mTc-Sestamibi at rest (activity 3 times higher), after 2 hours from first 99mTc-Sestamibi injection rest conventional acquisition 20 min later
Drug:
99mTc-Sestamibi
First intravenous injection between 80 and 150 MBq according to patient weight and second injection with 3-time-higher activity, 2 hours after the first For tomoscintigraphy
Thallium-201
Injection of thallium-201 (50% activity of first 99mTc-Sestamibi injection) For tomoscintigraphy

Locations

Country Name City State
France Service de Médecine Nucléaire - CLCC Jean Perrin Clermont Ferrand
France Service de Médecine Nucléaire - Hôpital de Brabois Vandœuvre les Nancy

Sponsors (1)

Lead Sponsor Collaborator
Central Hospital, Nancy, France

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Quality of images obtained with double isotope tomoscintigraphy and conventional tomoscintigraphy Bad; medium; good; very good day 0 No
Primary Nature of observed abnormalities obtained with double isotope tomoscintigraphy and conventional tomoscintigraphy Without abnormalities or artefacts (normal); with rest reversible abnormalities (ischemia); with rest non reversible abnormalities (infarction) day 0 No
See also
  Status Clinical Trial Phase
Terminated NCT02612701 - E-Cigarette Aerosol, Conventional Cigarette Smoke, and Myocardial Perfusion N/A
Completed NCT02494843 - Dynamic Effects of Online HDF on Cardiac Function and Myocardial Perfusion Utilising Cardiac MRI (CAMRID) N/A
Completed NCT02848703 - Study " COFLORES " N/A
Completed NCT02810106 - Assessment of Myocardial Perfusion by Tomography and Scintigraphy in Patients With Cardiac Stress Test With Ischemia
Completed NCT02655770 - Effect of Liraglutide on Diastolic Dysfunction on Cardiac MRI in Type 2 Diabetes Patients Phase 4